Cartesian Therapeutics, Inc. (RNAC)
| Market Cap | 430.53M |
| Revenue (ttm) | 47.94M |
| Net Income (ttm) | -282.38M |
| Shares Out | 25.41M |
| EPS (ttm) | -23.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 113,792 |
| Open | 17.61 |
| Previous Close | 17.55 |
| Day's Range | 16.85 - 18.20 |
| 52-Week Range | 11.67 - 42.60 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 40.80 (+140.85%) |
| Earnings Date | Nov 7, 2024 |
About RNAC
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; an... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for RNAC stock is "Strong Buy." The 12-month stock price forecast is $40.8, which is an increase of 140.85% from the latest price.
News
Cartesian Therapeutics: Uncertainty Remains
Cartesian Therapeutics' stock has rebounded sharply recently despite no significant news, driven partly by insider buying after a disappointing Phase 2b trial for Descartes-08 in myasthenia gravis. Th...
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment o...
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end
Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results
Cartesian Therapeutics, Inc.'s Descartes-08 mRNA CAR-T therapy shows promising Phase 2 results for myasthenia gravis without preconditioning chemotherapy. The company's RNA Armory platform enables pre...
Cartesian Therapeutics Announces New Employment Inducement Grant
GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatme...
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
Dr. Malik to deepen strategic leadership and provide regulatory and clinical development innovation expertise Dr. Malik to deepen strategic leadership and provide regulatory and clinical development i...
Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data
Cartesian Therapeutics, Inc. achieved positive results from the phase 2b study using Descartes-08 for the treatment of patients with myasthenia gravis; the End of phase 2 meeting with the FDA is expec...
Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study
Cartesian Therapeutics said on Tuesday that its experimental autoimmune disorder therapy met the main goal of a mid-stage trial.
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune dis...
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
Trial to assess outpatient administration without lymphodepleting chemotherapy in patients with SLE Trial to assess outpatient administration without lymphodepleting chemotherapy in patients with SLE
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 ...
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis remains on track for mid-2024 Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis remains on track for mid-2024
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseas...
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Topline data from Phase 2b trial of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
GAITHERSBURG, Md.--(BUSINESS WIRE)--Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today annou...
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GAITHERSBURG, Md.--(BUSINESS WIRE)--Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today annou...
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
Proposals approved at Company's special meeting of stockholders held March 27, 2024 Proposals approved at Company's special meeting of stockholders held March 27, 2024
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on track for mid-2024
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune dis...
Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
New facility expected to support expanded cGMP manufacturing of clinical and commercial supply of Company's pipeline of mRNA cell therapies for the treatment of autoimmune diseases